Apellis Pharmaceuticals, Inc.
NASDAQ:APLS
27.98 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 396.591 | 75.422 | 66.563 | 250.646 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 60.214 | 5.636 | 5.2 | 25.05 | 288.015 | 127.925 | 50.767 | 0 | 0 | 0 | 0 |
| Gross Profit
| 336.377 | 69.786 | 61.363 | 225.596 | -288.015 | -127.925 | -50.767 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.848 | 0.925 | 0.922 | 0.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 354.387 | 387.236 | 420.869 | 299.921 | 220.969 | 105.286 | 40.304 | 22.979 | 13.73 | 8.38 | 2.317 |
| General & Administrative Expenses
| 500.815 | 277.163 | 176.771 | 139.401 | 67.046 | 22.639 | 10.463 | 4.304 | 6.357 | 2.908 | 1.706 |
| Selling & Marketing Expenses
| -1.704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 499.111 | 277.163 | 176.771 | 139.401 | 67.046 | 22.639 | 10.463 | 4.304 | 6.357 | 2.908 | 1.706 |
| Other Expenses
| -0.727 | -0.288 | 1.362 | -0.501 | -0.175 | -0.111 | 0.012 | 0.158 | 0.006 | 0.062 | 0.068 |
| Operating Expenses
| 853.498 | 664.399 | 597.64 | 439.322 | 288.015 | 127.925 | 50.767 | 27.282 | 20.087 | 11.294 | 4.03 |
| Operating Income
| -517.121 | -594.613 | -536.277 | -213.726 | -288.015 | -127.925 | -50.767 | -27.282 | -46.573 | -11.294 | -4.03 |
| Operating Income Ratio
| -1.304 | -7.884 | -8.057 | -0.853 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -9.375 | -56.89 | -209.725 | -129.303 | -16.691 | -0.025 | -0.142 | 0.158 | -26.48 | 0.062 | 0.068 |
| Income Before Tax
| -526.496 | -651.503 | -746.002 | -343.029 | -304.707 | -127.502 | -51.006 | -27.125 | -46.516 | -11.232 | -3.962 |
| Income Before Tax Ratio
| -1.328 | -8.638 | -11.207 | -1.369 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 2.132 | 0.669 | 0.352 | 1.845 | 5.109 | -0.533 | 0.251 | -27.282 | -26.537 | -0.443 | 0 |
| Net Income
| -528.628 | -652.172 | -746.354 | -344.874 | -309.816 | -127.502 | -51.006 | -27.125 | -46.516 | -10.788 | -3.962 |
| Net Income Ratio
| -1.333 | -8.647 | -11.213 | -1.376 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -4.45 | -6.15 | -8.84 | -4.59 | -4.98 | -2.34 | -3.68 | -1.5 | -2.57 | -0.6 | -0.22 |
| EPS Diluted
| -4.45 | -6.15 | -8.84 | -4.59 | -4.98 | -2.34 | -3.68 | -1.5 | -2.57 | -0.6 | -0.22 |
| EBITDA
| -515.417 | -584.5 | -533.005 | -209.426 | -282.842 | -125.075 | -50.601 | -27.282 | 6.399 | -11.288 | -4.023 |
| EBITDA Ratio
| -1.3 | -7.75 | -8.008 | -0.836 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |